- Home
- CWBC vs ABVX Comparison
CWBC vs ABVX Comparison
Compare CWBC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWBC
- ABVX
- Stock Information
- Founded
- CWBC 1989
- ABVX 2013
- Country
- CWBC United States
- ABVX France
- Employees
- CWBC N/A
- ABVX N/A
- Industry
- CWBC Major Banks
- ABVX
- Sector
- CWBC Finance
- ABVX
- Exchange
- CWBC Nasdaq
- ABVX Nasdaq
- Market Cap
- CWBC 304.6M
- ABVX 451.5M
- IPO Year
- CWBC 1996
- ABVX N/A
- Fundamental
- Price
- CWBC $18.05
- ABVX $6.89
- Analyst Decision
- CWBC Buy
- ABVX Strong Buy
- Analyst Count
- CWBC 3
- ABVX 5
- Target Price
- CWBC $20.67
- ABVX $33.80
- AVG Volume (30 Days)
- CWBC 54.1K
- ABVX 100.3K
- Earning Date
- CWBC 04-21-2025
- ABVX 03-24-2025
- Dividend Yield
- CWBC 2.70%
- ABVX N/A
- EPS Growth
- CWBC N/A
- ABVX N/A
- EPS
- CWBC 0.65
- ABVX N/A
- Revenue
- CWBC $120,399,000.00
- ABVX $11,172,999.00
- Revenue This Year
- CWBC $33.09
- ABVX $284.20
- Revenue Next Year
- CWBC $5.29
- ABVX N/A
- P/E Ratio
- CWBC $27.04
- ABVX N/A
- Revenue Growth
- CWBC 38.79
- ABVX 135.94
- 52 Week Low
- CWBC $15.57
- ABVX $4.77
- 52 Week High
- CWBC $22.89
- ABVX $14.75
- Technical
- Relative Strength Index (RSI)
- CWBC 61.07
- ABVX 50.24
- Support Level
- CWBC $17.51
- ABVX $6.54
- Resistance Level
- CWBC $18.14
- ABVX $7.83
- Average True Range (ATR)
- CWBC 0.49
- ABVX 0.54
- MACD
- CWBC 0.17
- ABVX 0.00
- Stochastic Oscillator
- CWBC 96.15
- ABVX 27.98
About CWBC Community West Bancshares
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the Company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.